Skip to main content

Table 1 Baseline characteristics

From: The effect of exenatide on fasting bile acids in newly diagnosed type 2 diabetes mellitus patients, a pilot study

ParametersT2DM patientsHealthy subjectsP-valuea
(n = 38)(n = 38)
Age, years48.2 ± 9.052.9 ± 15.70.074
Male, %17, 44.7%18, 47.4% 
Height, cm170.7 ± 9.4171.7 ± 6.020.572
Weight, kg93.1 ± 17.190.1 ± 8.30.722
BMI, kg/m231.2 (28.5, 35.1)30.8 (27.7, 33.9)0.684
TC, mmol/L5.05 ± 1.114.09 ± 0.77<0.01
HDL-C, mmol/L1.15 ± 0.461.14 ± 0.300.995
LDL-C, mmol/L2.92 ± 0.802.23 ± 0.54<0.01
TG, mmol/L2.16 (1.26, 4.21)1.30 (0.87, 2.07)<0.01
FPG, mmol/L9.19 ± 3.464.41 ± 0.95<0.01
FTBAs, μmol/L3.84 ± 2.063.87 ± 2.890.954
  1. Data presented as means ± SD or medians (interquartile range)
  2. P value was calculated by independent sample T test
  3. aT2DM patients vs. healthy subjects